Mar 18, 2022
Immutep to Present Biomarker and Multivariate Analysis from Phase IIb AIPAC Study in Metastatic Breast Cancer at ESMO’s Breast Cancer Congress 2022
Immutep Announces Second Japanese Patent Grant for LAG-3 Antagonist Antibody LAG525
Mar 09, 2022
Immutep Receives Constructive Feedback from US FDA on its Clinical Development Program for EFTI in Metastatic Breast Cancer
Feb 24, 2022
Immutep Appoints Lucy Turnbull as Non-Executive Director
Feb 23, 2022
Immutep to Present at Healthcare Investor Conferences
Feb 17, 2022
Immutep to Present New Data from the Phase II TACTI-002 Study of Efti at ESMO’s European Lung Cancer Congress 2022
Feb 11, 2022
Immutep Granted Australian Patent for Eftilagimod Alpha, a Soluble LAG-3 Protein, in Combination with a PD-1 Pathway Inhibitor
Jan 31, 2022
Immutep to Present at February Investor Conferences
Jan 24, 2022
Immutep Quarterly Activities Report
Dec 15, 2021
Immutep Advances IMP761 Manufacturing
Dec 01, 2021
Immutep Reports Good Safety from First Five Patients in Triple Combination Therapy Efti Study, Insight-003
Nov 19, 2021
Immutep Successfully Completes Recruitment for Phase II TACTI-002 Study of LAG-3 Therapy, Eftilagimod Alpha
